Connection

Thomas Keane to Male

Back to Details
This is a "connection" page, showing publications Thomas Keane has written about Male.
Thomas Keane
Connection Strength
0.568
Male
  1. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Curr Urol Rep. 2017 Jun; 18(6):41.
    View in: PubMed
    Score: 0.031
  2. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. World J Urol. 2013 Dec; 31(6):1327-32.
    View in: PubMed
    Score: 0.024
  3. Androgen deprivation therapy: past, present and future. BJU Int. 2012 Jun; 109 Suppl 6:1-12.
    View in: PubMed
    Score: 0.022
  4. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. Urology. 2010 Nov; 76(5):1162-7.
    View in: PubMed
    Score: 0.020
  5. The multi-disciplinary management of high-risk prostate cancer. Urol Oncol. 2012 Jan-Feb; 30(1):3-15.
    View in: PubMed
    Score: 0.019
  6. Evaluation of modern pathological criteria for positive margins in radical prostatectomy specimens and their use for predicting biochemical recurrence. BJU Int. 2009 Feb; 103(3):327-31.
    View in: PubMed
    Score: 0.017
  7. Perineal prostatectomy in the age of minimally invasive surgery. J Ark Med Soc. 2008 Sep; 105(3):67-8.
    View in: PubMed
    Score: 0.017
  8. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology. 2008 Jun; 71(6):1177-80.
    View in: PubMed
    Score: 0.016
  9. Pathologically confirmed port site metastasis after laparoscopic radical prostatectomy: case report and literature review. Urology. 2007 Dec; 70(6):1222.e9-11.
    View in: PubMed
    Score: 0.016
  10. Salvage options for biochemical recurrence after primary therapy for prostate cancer. Can J Urol. 2007 Dec; 14 Suppl 1:2-9.
    View in: PubMed
    Score: 0.016
  11. Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm. Can J Urol. 2007 Dec; 14 Suppl 1:24-7.
    View in: PubMed
    Score: 0.016
  12. Partial segmental thrombosis of corpus cavernosum: case report and review of world literature. Urology. 2005 Jul; 66(1):194.
    View in: PubMed
    Score: 0.014
  13. Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscess. Urology. 2004 Oct; 64(4):808-10.
    View in: PubMed
    Score: 0.013
  14. Tissue disposition of 5-o-carboranyluracil--a novel agent for the boron neutron capture therapy of prostate cancer. Nucleosides Nucleotides Nucleic Acids. 2004; 23(1-2):291-306.
    View in: PubMed
    Score: 0.012
  15. PC-SPES withdrawal response. Acta Oncol. 2004; 43(8):772-3.
    View in: PubMed
    Score: 0.012
  16. Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. J Urol. 2021 02; 205(2):554-560.
    View in: PubMed
    Score: 0.010
  17. Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV. Can J Urol. 2020 10; 27(5):10352-10362.
    View in: PubMed
    Score: 0.010
  18. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2020 Apr; 203(4):743-750.
    View in: PubMed
    Score: 0.009
  19. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019 04; 201(4):682-692.
    View in: PubMed
    Score: 0.009
  20. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357.
    View in: PubMed
    Score: 0.009
  21. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol Oncol. 2018 06; 36(6):310.e7-310.e13.
    View in: PubMed
    Score: 0.008
  22. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017 05; 35(5):183-191.
    View in: PubMed
    Score: 0.008
  23. The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology. 2017 Jun; 104:150-159.
    View in: PubMed
    Score: 0.008
  24. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-na?ve Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 10; 70(4):675-683.
    View in: PubMed
    Score: 0.007
  25. Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With Elevated Serum Prostate-specific Antigen Is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. Urology. 2016 Apr; 90:32-7.
    View in: PubMed
    Score: 0.007
  26. Avoiding obsolescence in advanced prostate cancer management: a guide for urologists. BJU Int. 2015 Feb; 115(2):188-97.
    View in: PubMed
    Score: 0.007
  27. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):334-41.
    View in: PubMed
    Score: 0.006
  28. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer. Am J Clin Oncol. 2014 Apr; 37(2):188-93.
    View in: PubMed
    Score: 0.006
  29. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014 Mar; 83(3):664-9.
    View in: PubMed
    Score: 0.006
  30. Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):80-6.
    View in: PubMed
    Score: 0.006
  31. Impact of prostate cancer on sexual relationships: a longitudinal perspective on intimate partners' experiences. J Sex Med. 2013 Dec; 10(12):3135-43.
    View in: PubMed
    Score: 0.006
  32. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013 Oct; 123(10):4344-58.
    View in: PubMed
    Score: 0.006
  33. Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1?year after diagnosis: an economic perspective. Support Care Cancer. 2013 Dec; 21(12):3461-9.
    View in: PubMed
    Score: 0.006
  34. Editorial comment. Urology. 2012 Sep; 80(3):563.
    View in: PubMed
    Score: 0.006
  35. Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. Value Health. 2012 Jul-Aug; 15(5):716-23.
    View in: PubMed
    Score: 0.006
  36. Editorial comment. Urology. 2012 Jul; 80(1):168.
    View in: PubMed
    Score: 0.006
  37. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul; 97(7):2315-24.
    View in: PubMed
    Score: 0.005
  38. Contemporary diagnosis and management of squamous cell carcinoma (SCC) of the penis. BJU Int. 2011 Nov; 108(9):1378-92.
    View in: PubMed
    Score: 0.005
  39. Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. Clin Nucl Med. 2011 Oct; 36(10):872-8.
    View in: PubMed
    Score: 0.005
  40. Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients. Int J Cancer. 2012 Jul 01; 131(1):158-64.
    View in: PubMed
    Score: 0.005
  41. Penile cancer: an analysis of socioeconomic factors at a southeastern tertiary referral center. Can J Urol. 2011 Feb; 18(1):5524-8.
    View in: PubMed
    Score: 0.005
  42. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int. 2011 Sep; 108(6):851-6; discussion 856-7.
    View in: PubMed
    Score: 0.005
  43. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011 Apr; 59(4):543-52.
    View in: PubMed
    Score: 0.005
  44. Autophagy is increased in prostate cancer cells overexpressing acid ceramidase and enhances resistance to C6 ceramide. Prostate Cancer Prostatic Dis. 2011 Mar; 14(1):30-7.
    View in: PubMed
    Score: 0.005
  45. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol. 2011 Feb; 29(1):3-9.
    View in: PubMed
    Score: 0.005
  46. Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. J Urol. 1990 Oct; 144(4):1004-9.
    View in: PubMed
    Score: 0.005
  47. Chronic calcific pancreatitis: combination ERCP and extracorporeal shock wave lithotripsy for pancreatic duct stones. South Med J. 2010 Jun; 103(6):505-8.
    View in: PubMed
    Score: 0.005
  48. Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care. 2010 May 01; 16(5):e121-30.
    View in: PubMed
    Score: 0.005
  49. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58.
    View in: PubMed
    Score: 0.005
  50. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8.
    View in: PubMed
    Score: 0.004
  51. Managing prostate cancer: the role of hormone therapy. Can J Urol. 2007 Dec; 14 Suppl 1:10-8.
    View in: PubMed
    Score: 0.004
  52. Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol. 2007 Oct; 85(1):7-16.
    View in: PubMed
    Score: 0.004
  53. Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol. 2008 Feb; 45(3):839-48.
    View in: PubMed
    Score: 0.004
  54. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11(1):46-52.
    View in: PubMed
    Score: 0.004
  55. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007 Sep; 6(9):1455-60.
    View in: PubMed
    Score: 0.004
  56. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007 Jun; 51(6):1606-15.
    View in: PubMed
    Score: 0.004
  57. Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther. 2006 Nov; 14(5):627-36.
    View in: PubMed
    Score: 0.004
  58. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46.
    View in: PubMed
    Score: 0.004
  59. Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. J S C Med Assoc. 2006 Aug; 102(7):241-9.
    View in: PubMed
    Score: 0.004
  60. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 2005 Dec; 96(9):1280-5.
    View in: PubMed
    Score: 0.004
  61. [Reevaluation of MAB therapy and progress of endocrine therapy]. Gan To Kagaku Ryoho. 2005 May; 32(5):705-28.
    View in: PubMed
    Score: 0.003
  62. The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol. 2005 Feb; 1(1):115-23.
    View in: PubMed
    Score: 0.003
  63. Experience with coapted gastric tube outlet and composite gastrointestinal reservoir for continent cutaneous urinary diversion. J Urol. 2004 Jan; 171(1):229-31.
    View in: PubMed
    Score: 0.003
  64. Concomitant intraoperative renal artery embolization and resection of complex renal carcinoma. J Vasc Surg. 2003 Sep; 38(3):446-50.
    View in: PubMed
    Score: 0.003
  65. Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft. Urol Oncol. 2003 Jan-Feb; 21(1):49-57.
    View in: PubMed
    Score: 0.003
  66. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology. 2002 Aug; 60(2):201-8.
    View in: PubMed
    Score: 0.003
  67. Diuretic renogram in a patient with a urinary diversion: avoiding a false-positive diagnosis of obstruction with an indwelling catheter. Clin Nucl Med. 2001 Jul; 26(7):631-2.
    View in: PubMed
    Score: 0.003
  68. Gunshot wounds to the ureter: a 40-year experience at Grady Memorial Hospital. J Urol. 2001 Jul; 166(1):119-21.
    View in: PubMed
    Score: 0.003
  69. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 2000 Dec; 13(12):1315-23.
    View in: PubMed
    Score: 0.002
  70. Evaluation of staging lymphadenectomy in prostate cancer. Urology. 1998 Oct; 52(4):663-7.
    View in: PubMed
    Score: 0.002
  71. Two cases of vasculitis of the urinary bladder: diagnostic and pathogenetic considerations. Arch Pathol Lab Med. 1998 Oct; 122(10):903-6.
    View in: PubMed
    Score: 0.002
  72. Enhanced control by radiotherapy of cervical lymph node metastases arising from nasopharyngeal carcinoma compared with nodal metastases from other head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 1997 Aug 01; 39(1):149-54.
    View in: PubMed
    Score: 0.002
  73. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology. 1995 Aug; 46(2):200-4.
    View in: PubMed
    Score: 0.002
  74. Outcome following radiotherapy in verrucous carcinoma of the larynx. Int J Radiat Oncol Biol Phys. 1995 Jun 15; 32(3):611-7.
    View in: PubMed
    Score: 0.002
  75. Gastric cancer: the case for a more selective policy in surgical management. J R Coll Surg Edinb. 1993 Aug; 38(4):208-12.
    View in: PubMed
    Score: 0.002
  76. Use of protective plastic sheath for prostatic biopsy. Urology. 1992 Jan; 39(1):88-9.
    View in: PubMed
    Score: 0.001
  77. Characterization of a new model of human prostatic cancer: the multicellular tumor spheroid. Int J Cancer. 1990 Aug 15; 46(2):238-44.
    View in: PubMed
    Score: 0.001
  78. Prostate-specific antigen. Superior serum marker for prostatic carcinoma. Ir J Med Sci. 1987 May; 156(5):138-41.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.